Skip to Main Content

As the Biden administration begins setting priorities, the Federal Trade Commission is poised to take a tougher stand on some pharmaceutical industry practices, given the potential for anti-competitive behavior to influence prescription drug prices.

The anticipation is fueled by two issues that have gained considerable attention in recent years. One has been notable dissent by two agency commissioners — both of whom are Democrats — over merger reviews. And the other is growing concern over the extent to which rebates paid by drug makers for favorable insurance coverage may be choking competition.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!